Skip to main content
Top
Published in: Breast Cancer Research 1/2002

01-07-2002 | Meeting abstract

Review of clinical trials

Author: RE Hendrick

Published in: Breast Cancer Research | Special Issue 1/2002

Login to get access

Excerpt

Clinical trials of full-field digital mammography to date have compared sensitivity, specificity, and receiver operating characteristic (ROC) curves of digital to screen-film mammography, typically in paired studies of the two modalities. The largest study to date has been conducted in women at two institutions in the USA involving 6,736 paired examinations of women aged 40 and over presenting for screening mammography at the University of Colorado and University of Massachusetts Medical Centers. Of 1,467 subjects recommended for additional evaluation on at least one modality, 181 biopsies were performed, yielding detection of 42 cancers. Nine cancers were detected only by digital mammography, 15 only by screen-film mammography, 18 by both, and 8 by neither modality. The difference in cancer detection was not statistically significant (P > 0.1). Digital mammography resulted in fewer recalls than screen-film (799 versus 1,007; P < 0.001). ROC curve areas were 0.74 for digital and 0.80 for screen-film (P > 0.1). Results of other trials conducted to date, primarily diagnostic studies for regulatory approval, will also be described, along with the design of the National Cancer Institute sponsored American College of Radiology Imaging Network (ACRIN) DMIST study of 49,500 women, which is currently underway. …
Metadata
Title
Review of clinical trials
Author
RE Hendrick
Publication date
01-07-2002
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 1/2002
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr530

Other articles of this Special Issue 1/2002

Breast Cancer Research 1/2002 Go to the issue

Meeting abstract

Imaging implants

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine